DOSAGE INDEX / SINGLE
5-Amino-1MQ
Research, reported schedules and supply planning.
Examine 5-Amino-1MQ research on NNMT, mouse metabolism, diet combinations and off-target effects, with clear limits on human weight-loss claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 2.5–5 mg total per day; the divided example is 2.5 mg twice daily
- Frequency
- Daily or divided twice daily
- Cycle / observation period
- No defined course in the extracted schedule
- Route / research model
- Subcutaneous
The source wording varies between per-day and per-administration amounts. The table, rather than the ambiguous range sentence, is summarized here.
Titration & progression
The phases below describe the named source example, not an instruction to increase a dose. Product-label schedules and research examples are identified separately.
| Phase | Amount per administration | Frequency |
|---|---|---|
| Days 1–2 | 2.5 mg | Daily |
| Days 3–28 | 5 mg | Daily |
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
28-day arithmetic example; the source does not define a full course: 135 mg total material. Use this total below, or enter a different documented total for comparison.
| Vial strength | Vials needed |
|---|---|
| 10 mg | 14 |
| 50 mg | 3 |
Calculated from the displayed schedule.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- 5-Amino-1MQ is a small-molecule research compound investigated as an inhibitor of nicotinamide N-methyltransferase, usually shortened to NNMT. It is not a peptide. The directly checked studies below concern cells and obese mice, not a demonstrated weight-loss treatment for people. Its scientific interest comes from a metabolic target, rather than from evidence that a commercially available product produces predictable human results. [1]
- The discovery report described lower body weight, white fat mass, fat-cell size and cholesterol in treated diet-induced obese mice. Food intake did not explain the reported effect. The authors did not observe adverse effects in that experimental setting. That last finding is bounded by the animals, exposure and observations in the study; it is not an established human safety profile. [1]
- A 2024 report found that 5-Amino-1MQ limited weight and fat-mass gain in obese mice and improved measures related to glucose regulation and liver fat. The study also investigated drug exposure across tissues and routes. Its screening identified activity against MAO-A, an additional pharmacological consideration beyond NNMT. The authors disclosed commercial relationships involving Ridgeline Therapeutics. [2]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 30 entries mapped from 2 source pages. Medical and supporting references are retained below; supplier entries are excluded.
- Original discovery study
- 2024 original study
- Nature Medicine (2014)Further reading · Listed in reference bibliography.
- Frontiers in Pharmacology (2024)Further reading · Listed in reference bibliography.
- PubMed (2021)Further reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- ResearchGate (2021)Further reading · Listed in reference bibliography.
- PMC (2022)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- Journal of Medicinal Chemistry (ACS)Further reading · Listed in reference bibliography.
- Biochemical Pharmacology (2018) Selective small-molecule NNMT inhibition with 5-Amino-1MQ in diet-induced obese mice, including the weight-based subcutaneous 11-day exposure.Further reading · Listed in reference bibliography.
- PMC — NNMT: a bad actor in fat makes good in liverFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.